Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1, FIH, Open-label, Nonrandomized, Multicenter Study of JZP815 in Participants With Advanced or Metastatic Solid Tumors Harboring Alterations in the MAPK Pathway

NCT05557045 is registered in ClinicalTrials.gov with Jazz Pharmaceuticals as lead sponsor.

NCT NCT05557045
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05557045 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1, FIH, Open-label, Nonrandomized, Multicenter Study of JZP815 in Participants With Advanced or Metastatic Solid Tumors Harboring Alterations in the MAPK Pathway
Lead sponsor
Jazz Pharmaceuticals
Phase
Phase 1
Overall status
Active, not recruiting
Start date
October 10, 2022
Completion date
April 1, 2028
Enrollment
98 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

advanced cancer, anaplastic thyroid cancer (atc), colorectal cancer (crc), melanoma, metastatic cancer, non-small cell lung cancer (nsclc), solid tumor